GLP-1RA = glucagon-like peptide-1 receptor agonists; mg = milligrams; SC = subcutaneous; PO = oral administration; DLE = discoid lupus erythematosus; T2DM = type 2 diabetes mellitus; FAERS = FDA Adverse Event Reporting System; DAEN = Database of Adverse Event Notifications; COPD = Chronic Obstructive Pulmonary Disease; – = not reported. Here, GLP1R is linked to chronic obstructive pulmonary disease.